AVAV is trading at approximately $136.43 (down 4%) as investors continue to react to developments regarding a securities class-action lawsuit tied to the SCAR/BADGER program and related contract issues.
- Multiple plaintiff firms reiterated calls this week for investors to seek lead-plaintiff status by the July 27, 2026, deadline, keeping legal and contract-termination risks in focus.
- The stock remains under pressure following a string of sharp declines triggered by prior corrective disclosures related to the program.
- Market sentiment continues to be weighed down by the potential financial and operational impacts of the ongoing litigation.